Targeted disruption of influenza A virus hemagglutinin in genetically modified mice reduces viral replication and improves disease outcome

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Wang, Song ^a   Chen, Chao ^a   Yang, Zhou ^a   Chi, Xiaojuan ^a   Zhang, Jing ^b   Chen, Ji Long ^a,b  

^a FUJIAN AGRICULTURE AND FORESTRY UNIVERSITY   (China)

^b INSTITUTE OF MICROBIOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ, HUMAN INFLUENZA A VIRUS; INFLUENZA VIRUS HEMAGGLUTININ; SMALL INTERFERING RNA;

ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL LINE; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENE VECTOR; GENETICS; INFLUENZA A VIRUS (H1N1); LEUKOPENIA; LUNG; MOUSE; ORTHOMYXOVIRIDAE INFECTIONS; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE; SPLEEN; THYMUS; TRANSGENIC MOUSE; VIROLOGY; VIRUS REPLICATION;

ANIMALS; CELL LINE; FEMALE; GENE EXPRESSION REGULATION, VIRAL; GENE KNOCKDOWN TECHNIQUES; GENETIC VECTORS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; LEUKOPENIA; LUNG; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; ORTHOMYXOVIRIDAE INFECTIONS; RNA INTERFERENCE; RNA, SMALL INTERFERING; SPLEEN; THYMUS GLAND; VIRUS REPLICATION;

EID: 84962900929     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep23746     Document Type: Article

References (55)

1. Palese, P., Young, J. F. Variation of influenza A, B, and C viruses. Science 215, 1468-1474 (1982).
2. Jagger, B. W. et al. An overlapping protein-coding region in influenza A virus segment 3 modulates the host response. Science 337, 199-204 (2012).
3. Palese, P. Influenza: old and new threats. Nat. Med. 10, S82-87 (2004).
4. Horimoto, T., Kawaoka, Y. Pandemic threat posed by avian influenza A viruses. Clin. Microbiol. Rev. 14, 129-149 (2001).
5. Guarnaccia, T. et al. Antigenic drift of the pandemic 2009 A(H1N1) influenza virus in A ferret model. PLoS Pathog 9, e1003354 (2013).
6. Ferguson, N. M. et al. Strategies for mitigating an influenza pandemic. Nature 442, 448-452 (2006).
7. Hota, S., McGeer, A. Antivirals and the control of influenza outbreaks. Clin. Infect. Dis. 45, 1362-1368 (2007).
8. Subbarao, K., Murphy, B. R., Fauci, A. S. Development of effective vaccines against pandemic influenza. Immunity 24, 5-9 (2006).
9. Daly, J. M., MacRae, S., Newton, J. R., Wattrang, E., Elton, D. M. Equine influenza: a review of an unpredictable virus. Vet. J. 189, 7-14 (2011).
10. De Clercq, E. Antiviral agents active against influenza A viruses. Nat Rev Drug Discov 5, 1015-1025 (2006).
11. Boltz, D. A., Aldridge, J. R. Jr., Webster, R. G., Govorkova, E. A. Drugs in development for influenza. Drugs 70, 1349-1362 (2010).
12. Dong, G. et al. Adamantane-resistant influenza a viruses in the world (1902-2013): frequency and distribution of M2 gene mutations. PLoS One 10, e0119115 (2015).
13. Nelson, M. I., Simonsen, L., Viboud, C., Miller, M. A., Holmes, E. C. The origin and global emergence of adamantane resistant A/H3N2 influenza viruses. Virology 388, 270-278 (2009).
14. Bloom, J. D., Gong, L. I., Baltimore, D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328, 1272-1275 (2010).
15. Hay, A. J., Hayden, F. G. Oseltamivir resistance during treatment of H7N9 infection. Lancet 381, 2230-2232 (2013).
16. Samson, M., Pizzorno, A., Abed, Y., Boivin, G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res. 98, 174-185 (2013).
17. Moscona, A. Medical management of influenza infection. Annu. Rev. Med. 59, 397-413 (2008).
18. Meister, G., Tuschl, T. Mechanisms of gene silencing by double-stranded RNA. Nature 431, 343-349 (2004).
19. Wilson, R. C., Doudna, J. A. Molecular mechanisms of RNA interference. Annu Rev Biophys 42, 217-239 (2013).
20. Tompkins, S. M., Lo, C. Y., Tumpey, T. M., Epstein, S. L. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc. Natl. Acad. Sci. USA 101, 8682-8686 (2004).
21. Ge, Q. et al. Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc. Natl. Acad. Sci. USA 101, 8676-8681 (2004).
22. Ge, Q. et al. RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc. Natl. Acad. Sci. USA 100, 2718-2723 (2003).
23. Wise, T., Schafer, D., Lowenthal, J., Doran, T. The use of RNAi and transgenics to develop viral disease resistant livestock. Dev Biol (Basel) 132, 377-382 (2008).
24. Jain, B. et al. In vitro validation of self designed "universal human Influenza A siRNA". Indian J. Exp. Biol. 53, 514-521 (2015).
25. Svancarova, P., Svetlikova, D., Betakova, T. Synergic and antagonistic effect of small hairpin RNAs targeting the NS gene of the influenza A virus in cells and mice. Virus Res. 195, 100-111 (2015).
26. Daniel-Carlier, N. et al. Viral infection resistance conferred on mice by siRNA transgenesis. Transgenic Res. 22, 489-500 (2013).
27. Pengyan, W. et al. Transgenic mouse model integrating siRNA targeting the foot and mouth disease virus. Antiviral Res. 87, 265-268 (2010).
28. Lin, L., Liu, Q., Berube, N., Detmer, S., Zhou, Y. 5?-Triphosphate-short interfering RNA: potent inhibition of influenza A virus infection by gene silencing and RIG-I activation. J. Virol. 86, 10359-10369 (2012).
29. Sui, H. Y. et al. Small interfering RNA targeting m2 gene induces effective and long term inhibition of influenza A virus replication. PLoS One 4, e5671 (2009).
30. Perrimon, N., Ni, J. Q., Perkins, L. In vivo RNAi: today and tomorrow. Cold Spring Harb Perspect Biol 2, a003640 (2010).
31. Stevens, J. et al. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science 312, 404-410 (2006).
32. Fan, K. et al. Role of Itk signalling in the interaction between influenza A virus and T-cells. J. Gen. Virol. 93, 987-997 (2012).
33. Liu, B. et al. Severe influenza A(H1N1)pdm09 infection induces thymic atrophy through activating innate CD8(+ )CD44(hi) T cells by upregulating IFN-gamma. Cell Death Differ. 5, e1440 (2014).
34. Yang, S. et al. Cross-protective immunity against influenza A/H1N1 virus challenge in mice immunized with recombinant vaccine expressing HA gene of influenza A/H5N1 virus. Virol J 10, 291 (2013).
35. La Gruta, N. L., Turner, S. J. T cell mediated immunity to influenza: mechanisms of viral control. Trends Immunol 35, 396-402 (2014).
36. Thomas, P. G., Keating, R., Hulse-Post, D. J., Doherty, P. C. Cell-mediated protection in influenza infection. Emerging Infect. Dis. 12, 48-54 (2006).
37. Monto, A. S. Vaccines and antiviral drugs in pandemic preparedness. Emerging Infect. Dis. 12, 55-60 (2006).
38. Lyall, J. et al. Suppression of avian influenza transmission in genetically modified chickens. Science 331, 223-226 (2011).
39. Grimm, D. et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441, 537-541 (2006).
40. Martin, J. N. et al. Lethal toxicity caused by expression of shRNA in the mouse striatum: implications for therapeutic design. Gene Ther. 18, 666-673 (2011).
41. McBride, J. L. et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc. Natl. Acad. Sci. USA 105, 5868-5873 (2008).
42. Boudreau, R. L., Martins, I., Davidson, B. L. Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs in vitro and in vivo. Mol Ther 17, 169-175 (2009).
43. Cao, W., Hunter, R., Strnatka, D., McQueen, C. A., Erickson, R. P. DNA constructs designed to produce short hairpin, interfering RNAs in transgenic mice sometimes show early lethality and an interferon response. J Appl Genet 46, 217-225 (2005).
44. Stevens, J. et al. Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science 303, 1866-01870 (2004).
45. Dreyfus, C., Ekiert, D. C., Wilson, I. A. Structure of a classical broadly neutralizing stem antibody in complex with a pandemic H2 influenza virus hemagglutinin. J. Virol. 87, 7149-7154 (2013).
46. Ge, S., Wang, Z. An overview of influenza A virus receptors. Crit. Rev. Microbiol. 37, 157-165 (2011).
47. Gamblin, S. J. et al. The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science 303, 1838-1842 (2004).
48. Leung, H. S. et al. Entry of influenza A Virus with a alpha2,6-linked sialic acid binding preference requires host fibronectin. J. Virol. 86, 10704-10713 (2012).
49. Ito, T. et al. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. J. Virol. 72, 7367-7373 (1998).
50. Khiabanian, H., Trifonov, V., Rabadan, R. Reassortment patterns in Swine influenza viruses. PLoS One 4, e7366 (2009).
51. Wang, S. et al. Influenza A virus-induced degradation of eukaryotic translation initiation factor 4B contributes to viral replication by suppressing IFITM3 protein expression. J. Virol. 88, 8375-8385 (2014).
52. Ouyang, J. et al. NRAV, a long noncoding RNA, modulates antiviral responses through suppression of interferon-stimulated gene transcription. Cell Host Microbe 16, 616-626 (2014).
53. Wang, S. et al. Transport of influenza virus neuraminidase (NA) to host cell surface is regulated by ARHGAP21 and Cdc42 proteins. J. Biol. Chem. 287, 9804-9816 (2012).
54. Wei, H. et al. Suppression of interferon lambda signaling by SOCS-1 results in their excessive production during influenza virus infection. PLoS Pathog 10, e1003845 (2014).
55. Yang, J. et al. eIF4B phosphorylation by pim kinases plays a critical role in cellular transformation by Abl oncogenes. Cancer Res. 73, 4898-4908 (2013).